Cathie Wood has seldom shied away from letting everyone know where she believes the next wave of market-changing businesses will come from. Though ARK Invest’s daily trades spark a ton of excitement, its latest buying in CRISPR Therapeutics (CRSP) is far from being a sudden shift. The speculative healthcare stock specializes in gene editing, a technology that’s a key component of Wood’s vision for transformational innovation. Think of gene editing the way investors thought of the internet back in the 90 ...

COMPASS Pathways plc (NASDAQ:CMPS) is among the Best Get Rich Fast Stocks to Buy Right Now. As of December 24, COMPASS Pathways plc (NASDAQ:CMPS) has a ‘Buy’ or equivalent rating from the majority of the analysts covering the stock. With a target price range of $8 to $40, the median price target of $15 translates to an upside potential of 119.14% from the current price. On December 17, Gavin Clark-Gartner, an analyst at Evercore ISI, reaffirmed a ‘Hold’ rating on COMPASS Pathways plc (NASDAQ:CMPS), keepin ...

ProKidney Corp. (NASDAQ:PROK) is among the Best Get Rich Fast Stocks to Buy Right Now. As of December 24, ProKidney Corp. (NASDAQ:PROK) has a “buy” rating from slightly more than half of the analysts covering the stock. While the price target ranges from $1 to $12, the median price target of $6.50 reflects an upside potential of 152.92%. Among the analysts bullish on the stock is Joseph Pantginis, an analyst at H.C. Wainwright, who assumed coverage on the company with a ‘Buy’ rating and a $12 price target ...

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) is among the Best Get Rich Fast Stocks to Buy Right Now. As of December 24, 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) has a ‘Buy’ or equivalent rating from 82% of the analysts covering the stock. While the price target ranges from $17 to $45, the one-year median price target of $33 translates to an upside potential of over 300%. On December 19, Scott Bizily, the CLO of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT), offloaded 1,635 shares of the company’s s ...

After a strong biotech rebound, one fund quietly walked away from sector beta, and the timing says more than the trade itself.Kentucky-based Aristides Capital fully exited its position in the iShares Biotechnology ETF (IBB 0.70%), reducing its portfolio by approximately $3.60 million, according to a November 13 SEC filing.What HappenedAccording to a filing with the Securities and Exchange Commission on November 13, Aristides Capital sold all 28,467 shares of the iShares Biotechnology ETF (IBB 0.70%) previou ...

*Real-time prices by Nasdaq Last Sale. Real-time quote and/or trade prices are not sourced from all markets. Ownership data provided by LSEG and Estimate data provided by FactSet. IBD, IBD Digital, IBD Live, IBD Weekly, Investor's Business Daily, Leaderboard, MarketDiem, MarketSurge and other marks are trademarks owned by Investor's Business Daily, LLC. Information in Investor's Business Daily is for informational and educational purposes only and should not be construed as an offer, recommendation, solicit ...

U.S. stocks traded mixed this morning, with the Dow Jones index falling around 0.1% on Friday.Following the market opening Friday, the Dow traded down 0.07% to 48,698.11 while the NASDAQ rose 0.12% to 23,641.67. The S&P 500 also rose, gaining, 0.11% to 6,939.71.Check This Out: Top 2 Utilities Stocks That Could Lead To Your Biggest Gains This MonthLeading and Lagging SectorsInformation technology shares rose by 0.4% on Friday.In trading on Friday, industrials stocks fell by 0.2%.Top HeadlineShares of Biohave ...

Red Cat Holdings, Inc. ( RCAT ) stock has been on a downward trend since October. The stock hit a 2025 high of about $15 before dropping almost 40% to the $9 range we see shares trading atI hold a Master’s degree in Cell Biology and began my career working for several years as a lab technician in a drug discovery clinic, where I gained extensive hands-on experience in cell culture, assay development, and therapeutic research. That scientific foundation gave me an appreciation for the rigor and challenges be ...

The reverse stock split is intended to enable Adicet to regain compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market. About Adicet Bio, Inc. Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Adicet is advancing a pipeline of "off-the-shelf†gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patie ...

SEATTLE, WA / ACCESS Newswire / December 26, 2025 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIRâ"¢ and ADAPTIR-FLEXâ"¢ platform technologies, today announced that it will conduct a reverse stock split of its outstanding shares of common stock, par value $0.001 per share ("Common Stock"), at a ratio of 1-for-18 (the "Reverse Stock Split"). The Reverse Stock Split is expected to become ...